IL262144D0 - T cell receptors - Google Patents

T cell receptors

Info

Publication number
IL262144D0
IL262144D0 IL262144A IL26214418A IL262144D0 IL 262144 D0 IL262144 D0 IL 262144D0 IL 262144 A IL262144 A IL 262144A IL 26214418 A IL26214418 A IL 26214418A IL 262144 D0 IL262144 D0 IL 262144D0
Authority
IL
Israel
Prior art keywords
cell receptors
receptors
cell
Prior art date
Application number
IL262144A
Other languages
Hebrew (he)
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB201606009 priority Critical
Priority to PCT/GB2017/050985 priority patent/WO2017175006A1/en
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of IL262144D0 publication Critical patent/IL262144D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
IL262144A 2016-04-08 2018-10-04 T cell receptors IL262144D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (en) 2016-04-08 2017-04-07 T cell receptors

Publications (1)

Publication Number Publication Date
IL262144D0 true IL262144D0 (en) 2018-11-29

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262144A IL262144D0 (en) 2016-04-08 2018-10-04 T cell receptors

Country Status (18)

Country Link
US (1) US20190092834A1 (en)
EP (1) EP3440105A1 (en)
JP (1) JP2019516357A (en)
KR (1) KR20180132844A (en)
CN (1) CN109563148A (en)
AU (1) AU2017246693A1 (en)
BR (1) BR112018070741A2 (en)
CA (1) CA3020214A1 (en)
CL (1) CL2018002859A1 (en)
CO (1) CO2018011972A2 (en)
CR (1) CR20180531A (en)
IL (1) IL262144D0 (en)
MX (1) MX2018012318A (en)
PE (1) PE20190335A1 (en)
PH (1) PH12018502158A1 (en)
RU (1) RU2018135248A3 (en)
SG (1) SG11201808797XA (en)
WO (1) WO2017175006A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
WO2020148372A1 (en) 2019-01-17 2020-07-23 Immunocore Limited Formulations
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
MX2014004326A (en) * 2011-10-14 2014-09-25 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d.
AU2014211454B2 (en) * 2013-01-29 2018-04-05 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch High avidity binding molecules recognizing MAGE-A1
US20170283481A1 (en) * 2014-07-09 2017-10-05 The Regents Of The University Of California Engineered Invariant Natural Killer T (iNKT) Cells and Methods of Making and Using Thereof

Also Published As

Publication number Publication date
AU2017246693A1 (en) 2018-11-22
CN109563148A (en) 2019-04-02
PE20190335A1 (en) 2019-03-07
KR20180132844A (en) 2018-12-12
WO2017175006A1 (en) 2017-10-12
MX2018012318A (en) 2019-07-04
BR112018070741A2 (en) 2019-02-12
RU2018135248A3 (en) 2020-09-23
CA3020214A1 (en) 2017-10-12
US20190092834A1 (en) 2019-03-28
JP2019516357A (en) 2019-06-20
SG11201808797XA (en) 2018-11-29
CO2018011972A2 (en) 2019-02-08
PH12018502158A1 (en) 2019-07-15
EP3440105A1 (en) 2019-02-13
RU2018135248A (en) 2020-05-12
CR20180531A (en) 2019-06-13
CL2018002859A1 (en) 2019-04-26

Similar Documents

Publication Publication Date Title
GB2531928B (en) Image-stitching for dimensioning
IL250583D0 (en) Anti-tigit antibodies
ZA201608378B (en) Improved t cell compositions
GB201817189D0 (en) Image-stitching for dimensioning
IL274903D0 (en) Cell
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
GB201803296D0 (en) No details
HK1253507A1 (en) Anti-ror1 antibodies
HK1246825A1 (en) Cell
GB201516146D0 (en) None
IL259048D0 (en) Anti-ror1 antibodies
AU359704S (en) Case
IL239830A (en) Case
GB201514875D0 (en) Receptor
GB201516266D0 (en) None
PL3509156T3 (en) Electrolyte solution
AU201616677S (en) Cylindres
GB201608691D0 (en) Electrode
HK1231632A1 (en) Battery
GB201521382D0 (en) Antibodies
GB201521391D0 (en) Antibodies
GB201521393D0 (en) Antibodies
GB201402728D0 (en) Phone
GB201507368D0 (en) Cell